Holen Sie sich die Stockscreener-App
12.01
6.10%
0.69
Handel nachbörslich:
12.03
0.02
+0.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$11.32
Offen:
$11.36
24-Stunden-Volumen:
3.09M
Relative Volume:
1.63
Marktkapitalisierung:
$1.58B
Einnahmen:
$175.51M
Nettoeinkommen (Verlust:
$-78.02M
KGV:
-22.66
EPS:
-0.53
Netto-Cashflow:
$-34.18M
1W Leistung:
+3.45%
1M Leistung:
+36.48%
6M Leistung:
+50.69%
1J Leistung:
+120.37%
1-Tages-Spanne:
$11.18
$12.10
1-Wochen-Bereich:
$11.18
$12.10
52-Wochen-Spanne:
$5.41
$12.10
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Vergleichen Sie AUPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
12.01 | 1.50B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-05-05 | Eingeleitet | Cowen | Outperform |
| 2020-01-10 | Eingeleitet | Jefferies | Buy |
| 2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Bestätigt | FBR & Co. | Outperform |
| 2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Aurinia Pharmaceuticals stock hits 52-week high at 11.81 USD - Investing.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2025 Earnings Call Transcript - MSN
Can machine learning forecast Aurinia Pharmaceuticals Inc. recoveryShort Squeeze Opportunities with Indicators - Newser
Zurcher Kantonalbank Zurich Cantonalbank Acquires 8,390 Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) - Defense World
Full technical analysis of Aurinia Pharmaceuticals Inc. stockFree Early Entry Tips With Low Risk Zone - Newser
What data driven models say about Aurinia Pharmaceuticals Inc.’s futureFree Expert Verified Stock Trade Ideas - Newser
Will Aurinia Pharmaceuticals Inc. stock go up soonHigh Conviction Stock Long-Term Summary - Newser
Aurinia Pharmaceuticals Reports Strong Q2 2025 Financial Results and Expands Share Repurchase Plan - MSN
Is Aurinia Pharmaceuticals Inc. stock ready for a breakoutHigh Probability Trade Outcome Prediction - Newser
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) (NASDAQ:AUPH) - Seeking Alpha
Aurinia (AUPH) Q2 Revenue Jumps 22% - AOL.com
Day 6 of Gains Streak for Aurinia Pharmaceuticals Stock with 32% Return (vs. 30% YTD) [8/5/2025] - Trefis
Major Moves in Aurinia Pharmaceuticals Stock: Insider Trading Unveiled - TipRanks
Aurinia Pharma director Tang buys $13.59m in shares - Investing.com India
Aurinia Pharma director Tang buys $13.59m in shares By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 12-Month High on Analyst Upgrade - Defense World
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Aurinia Pharmaceuticals stock hits 52-week high at 10.74 USD By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals stock hits 52-week high at 10.74 USD - Investing.com
Research Analysts Set Expectations for AUPH FY2026 Earnings - Defense World
Aurinia Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating - TipRanks
What is Leerink Partnrs’ Forecast for AUPH Q1 Earnings? - Defense World
What are the latest earnings results for Aurinia Pharmaceuticals Inc.Unprecedented profit potential - Jammu Links News
Published on: 2025-08-04 03:37:38 - Jammu Links News
What analysts say about Aurinia Pharmaceuticals Inc. stockCapitalize on emerging investment opportunities - Jammu Links News
What is the risk reward ratio of investing in Aurinia Pharmaceuticals Inc. stockBuild a portfolio that outperforms the market - Jammu Links News
Is it the right time to buy Aurinia Pharmaceuticals Inc. stockAchieve superior capital gains with smart trades - Jammu Links News
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Just Beat EPS By 9.1%: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration - MSN
What catalysts could drive Aurinia Pharmaceuticals Inc. stock higher in 2025Unlock rapid growth potential in your portfolio - Jammu Links News
What drives Aurinia Pharmaceuticals Inc. stock priceFree Stock Market Mentorship - Jammu Links News
Should I hold or sell Aurinia Pharmaceuticals Inc. stock in 2025Free Investment Portfolio Suggestions - Jammu Links News
What are the technical indicators suggesting about Aurinia Pharmaceuticals Inc.Rapid growth opportunities - Jammu Links News
What is Aurinia Pharmaceuticals Inc. company’s growth strategyFastest-growing stock picks - Jammu Links News
How does Aurinia Pharmaceuticals Inc. generate profit in a changing economyRetirement Planning Forecasts For Consistent Profits - jammulinksnews.com
Aurinia Pharmaceuticals (AUPH): A High-Growth Biopharma Play with Strong Earnings Momentum and Strategic Pipeline Expansion - AInvest
Aurinia Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Published on: 2025-08-02 11:34:23 - beatles.ru
Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 6.1% Higher After Analyst Upgrade - Defense World
Q2 Earnings Estimate for AUPH Issued By HC Wainwright - Defense World
Aurinia Pharmaceuticals Inc. Added to High Probability Setup ListTechnical Entry Strategy for Beginners Explained - metal.it
RBC Raises Price Target on Aurinia Pharmaceuticals to $9 From $8, Keeps Outperform, Speculative Risk - MarketScreener
Aurinia 2025 Q2 Earnings Robust Net Income Growth at 2879.6% - AInvest
Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Aurinia Pharmaceuticals (NASDAQ:AUPH) Earns Buy Rating from HC Wainwright - Defense World
Equities Analysts Issue Forecasts for AUPH Q1 Earnings - Defense World
Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionPattern Breakout Prediction for Short Term - Newser
Contradictions in LUPKYNIS and AUR200: Insights from the Latest Earnings Call - AInvest
Aurinia: Q2 Earnings Snapshot - New Haven Register
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aurinia Pharmaceuticals Inc-Aktie (AUPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):